Page 5 - SUMMIT2018

Among the tools available for restoring
a healthy gut microbiota, Sartor
highlighted antibiotics, probiotics,
prebiotics, diet, combinations (antibiotics,
probiotics and prebiotics) and microbial
transplantation.
Regarding microbial transplantation,
Sartor emphasized that there are
conflicting results regarding its efficacy
and optimal treatment modality in
ulcerative colitis.

Contribution of gut microbiota-host cooperation to cancer

progression and therapy

covered the current body of data from Regarding microbiome signatures in
both experimental and clinical studies colorectal cancer (CRC), Fusobacterium
regarding the effects of microbiota nucleatum, Parvimonas micra and
composition on cancer progression translocation of oral pathogens to
and on regulating the efficacy of the gut are considered relevant
immunotherapy and chemotherapy. features in CRC and current research
Jobin noted that the evidence from is focusing on microbial genes that
animal models suggests biofilm- can be used as CRC biomarkers.
forming bacteria may be important Carbonnel presented an update on
in carcinogenesis through mucus the science of how the gut microbiota
degradation and subsequent may modulate responses to cancer
inflammation, but environment and immunotherapy and chemotherapy.
gene interactions are also important Based on the fact that superior efficacy
Christian Jobin presents on applications of gut for the cancer phenotype. Along these is observed in cancer immunotherapy
microbiota science to colorectal cancer. lines, Arumugam emphasized that and chemotherapy with the presence
fecal microbiome-based strategies of specific microbes, future strategies
Christian Jobin (Gainesville, USA), Mani may be useful for early diagnosis and of precision medicine will need to
Arumugam (Copenhagen, Denmark) treatment of colorectal adenoma or focus on the microbiome.
and Franck Carbonnel (Paris, France) carcinoma.

A set of 7 workshops focused on applications of gut
microbiota science to different clinical areas

Microbial signatures in children as predictors of chronic disease in

adult life

Mikael Knip (Helsinki, Finland) and
Samuli Rautava (Turku, Finland)
focused on how early microbial
contact in immune and metabolic
development provides the rationale
for new therapeutic approaches
to modifying microbial exposure
during the critical time periods of
fetal development and early infancy.
Knip discussed putative endogenous
and exogenous factors that may
contribute to the development of type
1 diabetes (T1D) during fetal and early
postnatal life. Rautava noted that
early gut colonization patterns in
early life can be modulated by mode
of delivery, antibiotics, prematurity
Early gut colonization patterns during early life. and possible fetal exposures.

5